'"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection

被引:89
作者
Lake, M. Alexandra [1 ,2 ]
Ambrose, Lyn R. [3 ]
Lipman, Marc C. I. [1 ,4 ]
Lowe, David M. [1 ,3 ]
机构
[1] Royal Free London NHS Fdn Trust, London, England
[2] UCL, Div Infect & Immun, London, England
[3] UCL, Inst Immun & Transplantat, Royal Free Campus,Pond St, London NW3 2QG, England
[4] UCL, UCL Resp, Div Med, Fac Med Sci, Royal Free Campus, London, England
来源
BMC MEDICINE | 2016年 / 14卷
关键词
Nontuberculous mycobacteria; Host defence; Primary immune deficiency; Interferon gamma; Interleukin; 12; Bronchiectasis; Cystic fibrosis; Immune response; INTERFERON-GAMMA-RECEPTOR; CYSTIC FIBROSIS BRONCHIECTASIS; OBSTRUCTIVE PULMONARY-DISEASE; RAPIDLY GROWING MYCOBACTERIA; HUMAN-IMMUNODEFICIENCY-VIRUS; COAL-WORKERS PNEUMOCONIOSIS; AVIUM COMPLEX INFECTION; NECROSIS-FACTOR-ALPHA; LUNG-DISEASE; IFN-GAMMA;
D O I
10.1186/s12916-016-0606-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The prevalence of nontuberculous mycobacterial (NTM) disease is rising. An understanding of known risk factors for disease sheds light on the immunological and physical barriers to infection, and how and why they may be overcome. This review focuses on human NTM infection, supported by experimental and in vitro data of relevance to the practising clinician who seeks to understand why their patient has NTM infection and how to further investigate. Discussion: First, the underlying immune response to NTM disease is examined. Important insights regarding NTM disease susceptibility come from nature's own knockouts, the primary immune deficiency disorders. We summarise the current knowledge surrounding interferon-gamma (IFN gamma)-interleukin-12 (IL-12) axis abnormalities, followed by a review of phagocytic defects, T cell lymphopenia and rarer genetic conditions known to predispose to NTM disease. We discuss how these define key immune pathways involved in the host response to NTM. Iatrogenic immunosuppression is also important, and we evaluate the impact of novel biological therapies, as well as bone marrow transplant and chemotherapy for solid organ malignancy, on the epidemiology and presentation of NTM disease, and discuss the host defence dynamics thus revealed. NTM infection and disease in the context of other chronic illnesses including HIV and malnutrition is reviewed. The role of physical barriers to infection is explored. We describe how their compromise through different mechanisms including cystic fibrosis, bronchiectasis and smoking-related lung disease can result in pulmonary NTM colonisation or infection. We also summarise further associations with host factors including body habitus and age. Summary: We use the presented data to develop an over-arching model that describes human host defences against NTM infection, where they may fail, and how this framework can be applied to investigation in routine clinical practice.
引用
收藏
页数:13
相关论文
共 122 条
  • [1] Prevalence of Nontuberculous Mycobacterial Lung Disease in US Medicare Beneficiaries
    Adjemian, Jennifer
    Olivier, Kenneth N.
    Seitz, Amy E.
    Holland, Steven M.
    Prevots, D. Rebecca
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 185 (08) : 881 - 886
  • [2] Ahmad Dina S, 2013, Avicenna J Med, V3, P37, DOI 10.4103/2231-0770.114121
  • [3] Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation
    Al-Anazi, Khalid Ahmed
    Al-Jasser, Asma M.
    Al-Anazi, Waleed Khalid
    [J]. FRONTIERS IN ONCOLOGY, 2014, 4
  • [4] Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis
    Andrejak, Claire
    Nielsen, Rikke
    Thomsen, Vibeke O.
    Duhaut, Pierre
    Sorensen, Henrik Toft
    Thomsen, Reimar Wernich
    [J]. THORAX, 2013, 68 (03) : 256 - 262
  • [5] Nontuberculous Pulmonary Mycobacteriosis in Denmark Incidence and Prognostic Factors
    Andrejak, Claire
    Thomsen, Vibeke O.
    Johansen, Isik S.
    Riis, Anders
    Benfield, Thomas L.
    Duhaut, Pierre
    Sorensen, Henrik T.
    Lescure, Francois-Xavier
    Thomsen, Reimar W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (05) : 514 - 521
  • [6] SUSCEPTIBILITY OF BEIGE MICE TO MYCOBACTERIUM-AVIUM - ROLE OF NEUTROPHILS
    APPELBERG, R
    CASTRO, AG
    GOMES, S
    PEDROSA, J
    SILVA, MT
    [J]. INFECTION AND IMMUNITY, 1995, 63 (09) : 3381 - 3387
  • [7] THE CLINICAL SPECTRUM OF PATIENTS WITH DEFICIENCY OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-1
    Averbuch, Diana
    Chapgier, Ariane
    Boisson-Dupuis, Stephanie
    Casanova, Jean-Laurent
    Engelhard, Dan
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (04) : 352 - 355
  • [8] Interferon Alpha Treatment of Patients with Impaired Interferon Gamma Signaling
    Bax, H. I.
    Freeman, A. F.
    Ding, L.
    Hsu, A. P.
    Marciano, B.
    Kristosturyan, E.
    Jancel, T.
    Spalding, C.
    Pechacek, J.
    Olivier, K. N.
    Barnhart, L. A.
    Boris, L.
    Frein, C.
    Claypool, R. J.
    Anderson, V.
    Zerbe, C. S.
    Holland, S. M.
    Sampaio, E. P.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (05) : 991 - 1001
  • [9] Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice
    Bermudez, LE
    Petrofsky, M
    Stevens, P
    [J]. IMMUNOLOGY, 1998, 94 (03) : 297 - 303
  • [10] Incidence and clinical implications of isolation of Mycobacterium kansasii:: Results of a 5-year, population-based study
    Bloch, KC
    Zwerling, L
    Pletcher, MJ
    Hahn, JA
    Gerberding, JL
    Ostroff, SM
    Vugia, DJ
    Reingold, AL
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) : 698 - +